Literature DB >> 9183768

Pathologic factors affecting postsplenectomy survival in dogs.

W L Spangler1, P H Kass.   

Abstract

The apparently high prevalence of splenomegaly in dogs, along with the surgical accessibility of the spleen, results in a relatively large number of splenectomies in dogs in clinical veterinary practice. Splenic nodular lesions are widely considered to be indicative of hemangiosarcoma and thus a disease that is ultimately fatal. This study correlates the results of complete pathologic evaluation and classification of 500 spleens obtained by splenectomy with survival information for each dog. Among the spleens examined, 257 of 500 (51.4%) were classified nonneoplastic and 241 (48.2%) were neoplastic; 2 (0.4%) were unclassified. Miscellaneous non-nodular splenomegaly accounted for 46 of 257 (18%) of the nonneoplastic lesions; nodular splenomegaly accounted for 206 of 257 (79%) of nonneoplastic splenic lesions and was composed of lymphoid hyperplastic nodules and associated hematomas, hyperplastic lymphoid nodules alone, or hematomas with no apparent underlying cause. Nodular neoplastic diseases of the spleen were divided among benign tumors (11.5%) and a variety of primary sarcomas. Hemangiosarcoma made up 51% of splenic malignancies but accounted for less than 25% of the spleens evaluated. Survival of dogs with hematomas associated with nonneoplastic conditions of the spleen was markedly different from that in dogs with hemangiosarcoma-associated hematomas, even though most could not be effectively differentiated on gross inspection. Two month postoperative survival was 83% for dogs with nonneoplastic-related hematomas, whereas only 31% of dogs with hemangiosarcoma, with or without associated hematomas, were alive after 2 months. Twelve-month survival times were 64% and 7%, respectively. An overall postsplenectomy survival rate of 52% was based on the number of dogs surviving for a minimum of 6 months postoperatively.

Entities:  

Mesh:

Year:  1997        PMID: 9183768     DOI: 10.1111/j.1939-1676.1997.tb00085.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  22 in total

1.  Primary peri-aortic hemangiosarcoma in a dog.

Authors:  Justin Guinan; Anthony Fischetti; Ana Paula Garate; Serge Chalhoub
Journal:  Can Vet J       Date:  2012-11       Impact factor: 1.008

2.  Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001-2013).

Authors:  Steve G Patten; Sarah E Boston; Gabrielle J Monteith
Journal:  Can Vet J       Date:  2016-08       Impact factor: 1.008

3.  Partial splenectomy for incidentally detected non-ruptured splenic lesions in dogs: 18 cases (2004-2018).

Authors:  Kaustubh R Dongaonkar; Daniel Linden; Jacqueline R Davidson; Harry W Boothe; D Michael Tillson; Brad M Matz
Journal:  Can Vet J       Date:  2019-11       Impact factor: 1.008

4.  Canine Non-Angiogenic, Non-Myogenic Splenic Stromal Sarcoma: a Retrospective Clinicopathological Analysis and Investigation of Podoplanin as a Marker of Tumour Histogenesis.

Authors:  Brittany M Wittenberns; Douglas H Thamm; Eric P Palmer; Daniel P Regan
Journal:  J Comp Pathol       Date:  2021-08-27       Impact factor: 1.083

5.  Development and validation of a multivariable model and online decision-support calculator to aid in preoperative discrimination of benign from malignant splenic masses in dogs.

Authors:  Kristine E Burgess; Lori Lyn Price; Ryan King; Manlik Kwong; Eliza Grant; Katherine A Olson; Jeremiah A Lyons; Nicholas A Robinson; Kristin M Wendelburg; John Berg
Journal:  J Am Vet Med Assoc       Date:  2021-06-15       Impact factor: 1.936

6.  Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

Authors:  Heather L Gardner; Cheryl A London; Roberta A Portela; Sandra Nguyen; Mona P Rosenberg; Mary K Klein; Craig Clifford; Douglas H Thamm; David M Vail; Phil Bergman; Martin Crawford-Jakubiak; Carolyn Henry; Jennifer Locke; Laura D Garrett
Journal:  BMC Vet Res       Date:  2015-06-11       Impact factor: 2.741

7.  Clinical Outcomes of Surgically Managed Spontaneous Tumors in 114 Client-owned Dogs.

Authors:  Ji-Won Choi; Hun-Young Yoon; Soon-Wuk Jeong
Journal:  Immune Netw       Date:  2016-04-28       Impact factor: 6.303

8.  Retrospective evaluation of thrombocytopenia and tumor stage as prognostic indicators in dogs with splenic hemangiosarcoma.

Authors:  Alison R Masyr; Aaron K Rendahl; Amber L Winter; Antonella Borgatti; Jaime F Modiano
Journal:  J Am Vet Med Assoc       Date:  2021-03-15       Impact factor: 1.936

9.  Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma.

Authors:  Heather Wilson-Robles; Tasha Miller; Jill Jarvis; Jason Terrell; Theresa Kathleen Kelly; Thomas Bygott; Mhammed Bougoussa
Journal:  BMC Vet Res       Date:  2021-06-29       Impact factor: 2.741

10.  Single agent polysaccharopeptide delays metastases and improves survival in naturally occurring hemangiosarcoma.

Authors:  Dorothy Cimino Brown; Jennifer Reetz
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-05       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.